ArticleGastroenterology report2025
Comparative performance of the GAAD and ASAP scores in predicting early-stage hepatocellular carcinoma.
Article in Gastroenterology report, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed.
- Distinct Alpha-Fetoprotein Trajectories Preceding Hepatocellular Carcinoma Diagnosis: A Latent Class Mixed-Model Analysis.Cancers · 2026Article
- Article
- Development of a longitudinal predictive model for hepatocellular carcinoma occurrence in patients with chronic hepatitis B.Scientific reports · 2026Article
- Protein Induced by Vitamin K Absence or Antagonist II in Primary Liver Cancer: Basic Research Insights and Clinical Applications.Journal of clinical and translational hepatology · 2025Review
- Utility of Biomarker Panels in the Surveillance and Monitoring of Hepatocellular Carcinoma: Consensus Statements from an International Delphi Panel.Liver cancer · 2025Article
- Performance of GAAD and GALAD Biomarker Panels for HCC Detection in Patients with MASLD or ALD Cirrhosis.Cancers · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: The gender, age, alpha-fetoprotein (AFP), and des-gamma-carboxy prothrombin (GAAD) score is a recent predictive tool for hepatocellular carcinoma (HCC) but lacks comparison with the AFP, Sex, Age, and Protein induced by vitamin K absence-II (ASAP) score, which uses similar parameters with different assays and formulas. Our study aimed to evaluate the performance differences between these two scores. Methods: Blood samples from 622 patients with chronic liver diseases at Songklanagarind Hospital between 20 April 2023 and 31 December 2023 were analyzed. The cutoffs for the ASAP and GAAD scores were established as 0.526 and 2.570, respectively, and HCC diagnoses followed the European Association for the Study of the Liver (EASL) or the American Association for the Study of Liver Diseases (AASLD) guidelines. Results: HCC diagnoses were observed in 28.6% of patients, with 48.3% diagnosed with early-stage diseases (Barcelona Clinic Liver Cancer stage 0 = 23, A = 63). Hepatitis B virus infection (40.4%) and metabolic dysfunction-associated steatotic liver disease (21.3%) were predominant causes. The area under the receiver operating characteristic curve (AUROCs) of the ASAP and GAAD scores for predicting all-stage HCC were comparable (0.933 vs 0.937, Conclusion: Both the GAAD and ASAP scores demonstrated excellent and comparable abilities in HCC detection across all stages, unaffected by cirrhosis or etiological differences.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.